Cinven to invest in Linden Capital-backed Regenity Biosciences.

Cinven, a private equity firm, agreed to invest in Linden Capital-backed Regenity Biosciences, a developer and manufacturer of bioresorbable technologies. Financial terms were not disclosed. “Regenity has built an impressive position in regenerative biomaterials, underpinned by technical depth, a strong culture, and a clear commitment to improving patient outcomes alongside its customers. We look forward to partnering with Linden and Regenity’s leadership on this next phase of growth," Julia Kahr, Cinven Partner and Head of the North America Regional.